Treatment Strategies to Control Blood Pressure in People With Hypertension in Tanzania and Lesotho
Authors: Mapesi Herry , Rohacek Martin , Vanobberghen Fiona , Gupta Ravi , Wilson Herieth Ismael , Lukau Blaise , Amstutz Alain , Lyimo Aza , Muhairwe Josephine , Senkoro Elizabeth , Byakuzana Theonestina , Nkouabi Jacqueline , Mbunda Geofrey , Siru Jamali , Tarr Ayesha , Ramapepe Elsie , Mphunyane Madavida , Oehri Johanna , Nemtsova Valeriya , Yan Xiaohan , Bresser Moniek , Glass Tracy Renée , Paris Daniel Henry , Fink Günther , Gingo Winfrid , Labhardt Niklaus Daniel , Burkard Thilo , Weisser Maja 
Published: January 2025

ImportanceHypertension is the primary cardiovascular risk factor in Africa. Recently revised World Health Organization guidelines recommend starting antihypertensive dual therapy; clinical efficacy and tolerability of low-dose triple combination remain unclear.ObjectivesTo compare the effect of 3 treatment strategies on blood pressure control among persons with untreated hypertension in Africa.Design, Setting, and ParticipantsThis was an open-label, parallel, 3-arm randomized clinical trial to evaluate noninferiority of a strategy starting 2 pills vs full-dose monotherapy with stepped escalation (noninferiority margin 10%) and superiority of starting low-dose 3 pills vs monotherapy allowing for monthly up titration. Recruitment lasted from March 5, 2020, to March 30, 2022. The setting was 2 hospitals in rural Lesotho and Tanzania. Participants included nonpregnant Black African individuals 18 years and older with uncomplicated, untreated hypertension (standardized office blood pressure ≥140 mm Hg systolic or ≥90 mm Hg diastolic).InterventionsParticipants were randomized 2:2:1 to stepped monotherapy (amlodipine, 10 mg, with escalation to add hydrochlorothiazide if needed), 2-pill strategy (amlodipine, 5 mg; losartan, 25 mg), or 3-pill strategy (amlodipine, 2.5 mg; losartan, 12.5 mg; hydrochlorothiazide, 6.25 mg). Drugs were up titrated monthly until reaching the target blood pressure (≤ 130/80 mm Hg for participants aged &amp;lt;65 years; ≤140/90 mm Hg for those aged ≥65 years).Main Outcomes and MeasuresProportion of participants reaching target blood pressure at 12 weeks.ResultsOf 1761 participants screened, 1268 were enrolled (median [IQR] age, 54 [45-65] years; 914 female [72%]), with 505 in the monotherapy cohort, 510 in the 2-pill cohort, and 253 in the 3-pill cohort. In noninferiority analyses, 207 of 370 participants (56%) receiving the 2-pill strategy and 173 of 338 participants (51%) receiving the stepped monotherapy strategy achieved the blood pressure target (adjusted odds ratio [aOR], 1.18; 95% CI, 0.87-1.61), fulfilling noninferiority. In superiority analyses after multiple imputation for missing outcome data, 57% of participants receiving the 3-pill strategy, 55% receiving the 2-pill strategy, and 49% receiving the stepped monotherapy strategy reached the target blood pressure (aOR, 1.24; 95% CI, 0.94-1.63; P = .12 and aOR, 1.28; 95% CI, 0.91-1.79; P = .16 for the 2-pill and 3-pill vs stepped monotherapy strategies, respectively).Conclusions and RelevanceResults of this randomized clinical trial show that in 2 African settings, for adults with uncomplicated untreated hypertension, a strategy starting a 2-pill low-dose treatment was noninferior to starting stepped monotherapy. Two-pill and 3-pill low-dose strategies were not superior to stepped monotherapy. Wide CIs preclude the ability to rule out potentially clinically important effects of the additional pill strategies for hypertension control.Trial RegistrationClinicalTrials.gov Identifier: NCT04129840